drugset / Trial / NCT01001195

Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution

NCT01001195

Phase 2 Completed 165 enrolled Allergan
RandomizedParallel-groupTriple-blindTreatment

Summary

This study will evaluate the safety, efficacy and dose-response of AGN-210669. This study will also compare AGN-210669 with bimatoprost ophthalmic solution (LUMIGAN®).

Timeline

Start
2009-11
Primary completion
2010-04
Completion
2010-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bimatoprost Other / unclassified 0.03 % Other
Subject SIMENEPAG ISOPROPYL Small molecule 0.05 % Other
Subject SIMENEPAG ISOPROPYL Small molecule 0.075 % Other
Subject SIMENEPAG ISOPROPYL Small molecule 0.1 % Other